Compare Constellation Energy Corporation (CEG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Constellation Energy Corporation vs Novo Nordisk A/S — how do they compare? Constellation Energy Corporation trades at $279.71 (market cap $98.63B), while Novo Nordisk A/S trades at $46.2 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.1× Constellation Energy Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| CEG | NVO | |
|---|---|---|
Market Cap | $98.63B | $207.85B |
Sector | Energy | Health |
52-Week High | $403.95 | $63.98 |
52-Week Low | $236.50 | $35.29 |
Enterprise Value | $122.63B | $222.55B |
Dividend Yield | 0.61% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) trades at $279.75, up 3.45% in the past 24 hours, with a bullish technical signal and strong support near $277. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised 2026 guidance, driven by nuclear power demand and new contracts like the Walmart PPA. Revenue growth is robust, with 2026 projections at $31.3 billion, and profitability metrics show a net margin of 11.08% and ROE of 15.26%.
The outlook is positive, with a consensus price target of $332.13 implying 19% upside, supported by AI-driven electricity demand and nuclear fleet advantages. Risks include execution challenges in integrating acquisitions and potential regulatory shifts. Analysts are bullish, with 70% buy ratings, citing long-term growth from data center power needs.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
